Bladder cancerA study looking at matching treatment to the individual make up of bladder cancer (GUSTO)
This study is looking at tissue samples in detail to try to match people to treatment for bladder cancer.
Bladder cancer
Cancer of the muscular sack in the abdomen where urine collects before it is passed out of the body.
Available
Available
A trial looking at V940 and pembrolizumab for urothelial (urinary tract) cancer after surgery
This trial is looking at the combination of a treatment called V940 and pembrolizumab for urothelial cancer.
A trial looking at erdafitinib and cetrelimab for bladder cancer (SOGUG-NEOWIN)
This trial is looking at erdafitinib on its own or in combination with cetrelimab for bladder cancer that has spread into or through the muscle layer.
A study looking at how people manage symptoms that could be cancer (CLOCS-2)
This study is looking at the products people buy to help with vague symptoms that could be cancer.
A study looking at how bacteria in the gut affects treatment for pelvic cancer (PELICAN-23)
This study is looking to see if gut bacteria the microbiome affects how well treatment works for certain cancers that started in the pelvis.
A trial of sacituzumab govitecan for urothelial cancer (urinary tract cancer) that has spread (TROPHY U-01)
This trial is looking at a new drug called sacituzumab govitecan on its own or in combination with other cancer treatments for urinary tract cancer.
A trial of atezolizumab before surgery for urothelial cancer of the bladder (INVEST)
This trial is looking at having atezolizumab directly into the bladder followed by surgery.
A trial looking at atezolizumab for cancers of the urinary tract (AURORA)
The aim of their treatment is to control symptoms (palliative treatment).
A trial looking at 3 cycles of chemotherapy for urothelial cancer (urinary tract cancer) (DISCUS)
This trial is comparing 3 cycles of chemotherapy with the standard 6 cycles for urinary tract cancer that has spread.
A study of durvalumab and the vaccine S-488210/S-488211 for bladder cancer (DURANCE)
This study is looking at durvalumab in combination with the S-488210/S-488211 vaccine to treat non muscle invasive bladder cancer.